In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 monthsObjective responses were also seen in 4 of 13 response-evaluable EGFR mutant (EGFRmut) NSCLC patients confirming the activity of AFM24 and atezolizumab in heavily pretreated NSCLC patientsIn both NSCLC cohorts, the combination therapy show ...

Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic cancers in the ongoing AFM24-102 phase 1/2a studyThe FDA's Fast Track designation was granted after its review of the initial efficacy data of the EGFR wild-type cohort from the AFM24-102 studyFast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious condi ...

MANNHEIM, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2024 Annual General Meeting of Shareholders (the "Annual Meeting") will be held on June 26, 2024 at 09:00 a.m. CET at the offices of De Brauw Blackstone Westbroek N.V., Burgerweeshuispad 201, 1076 GR Amsterdam, the Netherlands. The notice and agenda of the Annual ...

One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks. Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points. Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many upstart biotech firms fail to co ...

In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led to a disease control rate of 73.3% (11/15), including 4 objective responses (1 complete and 3 partial responses)As of the March 18, 2024 data cut-off, the median progression free survival was 5.9 months and 3 of 4 responses were ongoingThe poster of the ongoing study will be presented on June 1, 2024, 9:00 a.m. ...

In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led to a disease control rate of 73.3% (11/15), including 4 objective responses (1 complete and 3 partial responses) As of the March 18, 2024 data cut-off, the median progression free survival was 5.9 months and 3 of 4 responses were ongoing The poster of the ongoing study will be presented on June 1, 2024, 9:00 a. ...

Many analysts forecast that an interest rate cut is coming by September. When that happens, speculative capital is likely to move away from large-cap stocks. That’s why it’s a good time to consider small-cap stocks to buy.  As interest rates went higher in 2022 and 2023, small-cap stocks fell out of favor. Many of these stocks are those of small, early stage companies that are not yet profitable. The rising cost of capital due to higher interest rates can most affect these companies.  That’s the risk that c ...

Shares of Affimed N.V. (AFMD) have gained 0.6% over the past four weeks to close the last trading session at $5.35, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.20 indicates a potential upside of 146.7%.The average comprises five short-term price targets ranging from a low of $5 to a high of $25, with a standard deviation of $8.87. While the lowest estimate indicates a de ...

AFM24与atezolizumab相结合的第2期研究 - Affimed N.V.宣布其AFM24与atezolizumab相结合的第2期研究初步数据已被接受用于海报展示[1] - AFM24是一种四价、双特异性的ICE®，通过结合CD16A和表皮生长因子受体（EGFR）来激活先天免疫系统，以杀死癌细胞[3] - Affimed是一家致力于通过实现先天免疫系统未开发潜力来帮助患者抗击癌症的临床阶段免疫肿瘤学公司[4]

A downtrend has been apparent in Affimed N.V. (AFMD) lately. While the stock has lost 12% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the s ...